Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olanzapine-induced mania.

Journal of osteopathic medicine·2024
Same author

Significant cognitive impairment likely associated with COVID-19 infection with relatively nonsevere symptoms.

Journal of osteopathic medicine·2022
Same author

Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults.

The Journal of the American Osteopathic Association·2019
Same author

A Case Study of Gamma Waves in a Woman with Recent Psychotic Symptoms.

The Neurodiagnostic journal·2016
Same author

Abdominal Trigger Points and Psychological Function.

The Journal of the American Osteopathic Association·2016
Same author

Alexithymia: Should This Personality Disorder Be Considered During Treatment of Patients With Mental Illness?

Journal of psychosocial nursing and mental health services·2015

Related Experiment Videos

SSRIs & the risk of abnormal bleeding.

Roy R Reeves1, P Melonee Wise, Sera K Cox

  • 1Montgomery VA Medical Center, Jackson, MS 39216, USA. roy.reeves@med.va.gov

Journal of Psychosocial Nursing and Mental Health Services
|May 5, 2007
PubMed
Summary

Selective serotonin reuptake inhibitors (SSRIs) may affect blood clotting, though the bleeding risk is generally low. Monitor patients for bruising or bleeding, especially those with existing risks.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
  • Interactions between SSRIs and hematological functioning, particularly platelet function, require further investigation.
  • Current data on SSRI effects on platelet function and bleeding risk are limited.

Purpose of the Study:

  • To highlight the need for more research into SSRI and hematological interactions.
  • To emphasize the potential, albeit low, risk of bleeding associated with SSRI use.
  • To provide guidance on patient monitoring and cautionary measures.

Main Methods:

  • Review of existing literature on SSRI and hematological interactions.
  • Analysis of reported cases of bleeding in patients taking SSRIs.

Related Experiment Videos

  • Consideration of factors influencing bleeding risk.

    • Main Results:

    • The risk of significant bleeding with SSRI treatment appears low.
    • Minor bleeding events can occur and warrant clinical attention.
    • Abnormal bleeding or bruising requires thorough etiological assessment.

    Conclusions:

    • Patients on SSRIs, especially those with blood dyscrasias or on concomitant medications affecting platelets, should be monitored for bruising and bleeding.
    • Caution is advised when initiating SSRIs in patients with pre-existing bleeding risks, including those using NSAIDs or aspirin.